Novo submits high-dose Wegovy for FDA approval using voucher / Endpoints

Max Bayer / endpoints - Novo Nordisk submitted a higher dose of its obesity drug Wegovy for FDA approval and is using a recently-won voucher to expedite the review. The company said Wednesday that it submitted ...

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #publichealth #biotech #drugdevelopment #fda

Novo Nordisk seeks FDA approval of higher-dose Wegovy

3 months / beckershospitalreview / Paige Twenter

Novo submits high-dose Wegovy for FDA approval using voucher

3 months / endpoints / Max Bayer

Saturday, November 29, 2025, 5:21 pm / permalink 16400 / 2 stories in 3 months

Related Stories

Novo Nordisk GLP‑1 Trials Fail to Check Alzheimer’s Progression / 3 months
Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 2 months
Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 8 days
Novo Nordisk slashes prices for Ozempic and Wegovy / 3 months
FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 5 wks
FDA rejects Corcept’s cortisol modulator triggering setback / 2 months
FDA approves Rucaparib for advanced prostate cancer / 2 months

Related Tags

Obesity

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

GLP‑1 drugs associated with lower addiction risk in large study (4 days)

Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines (8 days)

Healthcare

Judge orders Leapfrog to remove safety grades for five Florida hospitals (21 hrs)

Daily multivitamin slows epigenetic aging in randomized COSMOS analysis (40 hrs)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

more #healthcare

Pharmaceuticals

Engineered CAR‑T cells secreting VEGF‑neutralizing scFvs boost solid‑tumor activity (2 days)

White House briefing triggered rapid drops in acetaminophen use in ERs (2 days)

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage (3 days)

more #pharmaceuticals

StackHealth Time Machine

NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.